Close

News

Merck announces positive results phase 3 trials of gefapixant 45 mg twice daily in patients with refractory or unexplained chronic cough

Merck, known as MSD outside the United States and Canada, has announced the results from two pivotal phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist,...

Mylan to Acquire Aspen’s Thrombosis Business in Europe

Mylan N.V. announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for EUR 641.9 million, subject to customary closing conditions and European regulatory clearances. The transaction is expected...

Bayer completes acquisition of UK-based biotech company KaNDy Therapeutics Ltd

Bayer, a global leader in women’s healthcare, announced that, further to its press release of August 11, 2020, it has now completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s...

Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets in Japan from Meiji Seika Pharma

Eisai Co., Ltd. announced that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide mesilate, "Equfina") in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020. In Japan,...

China shows off Covid-19 vaccines for first time

China has put its homegrown coronavirus vaccines on display for the first time, as the country where the contagion was discovered looks to shape the narrative surrounding the pandemic. High hopes hang on the small vials of liquid on show...

Sinovac Biotech’s COVID-19 vaccine enters phase 3 trial globally

A COVID-19 vaccine candidate developed by Beijing-based Sinovac Life Sciences Corp has obtained preliminary approval in Bangladesh for entering phase III clinical trials, the company. "Our vaccine has received approval from a national drug research council in Bangladesh and is...

ADMA Biologics Highlights Launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA Assay to Detect SARS-CoV-2 Neutralizing Antibodies in Plasma

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA assay for the detection of SARS-CoV-2 neutralizing antibodies in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read